Cargando…

Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1

The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues collected from patients with recurrent glioblastoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yue, Ng, Alphonsus H. C., Chow, Frances E., Everson, Richard G., Helmink, Beth A., Tetzlaff, Michael T., Thakur, Rohit, Wargo, Jennifer A., Cloughesy, Timothy F., Prins, Robert M., Heath, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241935/ https://www.ncbi.nlm.nih.gov/pubmed/34188042 http://dx.doi.org/10.1038/s41467-021-24293-4

Ejemplares similares

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
por: Lee, Alexander H., et al.
Publicado: (2021)

DDRE-23. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO LIPID PEROXIDATION INDUCED CELL DEATH
por: Morrow, Danielle, et al.
Publicado: (2021)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Galvani, Elena, et al.
Publicado: (2020)

A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
por: Cheng, Quan, et al.
Publicado: (2019)

LncRNA PELATON, a Ferroptosis Suppressor and Prognositic Signature for GBM
por: Fu, Haijuan, et al.
Publicado: (2022)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
por: Witt, Russell G., et al.
Publicado: (2022)

Anti-GBM-Nephritis
por: Windpessl, Martin, et al.
Publicado: (2023)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features
por: Rios Velazquez, Emmanuel, et al.
Publicado: (2015)

Differentiation of Human GBM From Non-GBM Brain Tissue With Polarization Imaging Technique
por: Liu, Yi-Rong, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
por: Cloughesy, Timothy F., et al.
Publicado: (2019)

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade
por: von Roemeling, Christina, et al.
Publicado: (2023)

Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells
por: Mukherjee, Sumit, et al.
Publicado: (2018)

Proteomics-based prognostic signature and nomogram construction of hypoxia microenvironment on deteriorating glioblastoma (GBM) pathogenesis
por: Wen, Ya-Dan, et al.
Publicado: (2021)

Prognostic impact of a lymphocyte activation-associated gene signature in GBM based on transcriptome analysis
por: Lan, Yujia, et al.
Publicado: (2021)

Recurrent anti-GBM disease with pulmonary artery aneurysms
por: Dixon, John, et al.
Publicado: (2016)

Advances in nanotechnology for the treatment of GBM
por: Wei, Dongyan, et al.
Publicado: (2023)

Anti-GBM disease with a mild relapsing course and low levels of anti-GBM autoantibodies
por: Segelmark, Mårten, et al.
Publicado: (2012)

Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines
por: Binder, Zev A., et al.
Publicado: (2016)

Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM
por: Liu, Bao, et al.
Publicado: (2022)

Transformation of membranous into anti-GBM nephritis
por: Imtiaz, S., et al.
Publicado: (2012)

Mitochondrial DNA Alterations in Glioblastoma (GBM)
por: Leão Barros, Mariceli Baia, et al.
Publicado: (2021)

The Role of Myeloid Cells in GBM Immunosuppression
por: Lin, Ya-Jui, et al.
Publicado: (2022)

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy
por: Mauzo, Shakuntala H., et al.
Publicado: (2019)

Histone H3 Phosphorylation in GBM: a New Rational to Guide the Use of Kinase Inhibitors in anti-GBM Therapy
por: Pacaud, Romain, et al.
Publicado: (2015)

Anti-GBM disease with positive serum anti-GBM antibodies but negative IgG deposition: A case report
por: Kazemzadeh, Kimia, et al.
Publicado: (2023)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Podocyte Depletion in Thin GBM and Alport Syndrome
por: Wickman, Larysa, et al.
Publicado: (2016)

Re-thinking the preclinical development of GBM therapeutics
por: Cosset, Érika, et al.
Publicado: (2018)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Using Light for Therapy of Glioblastoma Multiforme (GBM)
por: Vasilev, Alex, et al.
Publicado: (2020)

FAM72, Glioblastoma Multiforme (GBM) and Beyond
por: Ho, Nguyen Thi Thanh, et al.
Publicado: (2021)

Engineering Adenoviral Vectors with Improved GBM Selectivity
por: Bates, Emily A., et al.
Publicado: (2023)

A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomes
por: Bertolini, Irene, et al.
Publicado: (2019)

A necroptosis-related lncRNA signature was identified to predict the prognosis and immune microenvironment of IDH-wild-type GBM
por: Song, Chong, et al.
Publicado: (2022)

Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening
Publicado: (1986)

A Fourteen Gene GBM Prognostic Signature Identifies Association of Immune Response Pathway and Mesenchymal Subtype with High Risk Group
por: Arimappamagan, Arivazhagan, et al.
Publicado: (2013)

FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature
por: Liang, Lu, et al.
Publicado: (2022)

ADAR2 Protein Is Associated with Overall Survival in GBM Patients and Its Decrease Triggers the Anchorage-Independent Cell Growth Signature
por: Cesarini, Valeriana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rm1h3gm0rkp1qeh37kgrh7mvr5